The Newsroom
Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.
Press Release
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
July 16, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi to Effect Reverse Stock Split
July 5, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
June 27, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
June 11, 2024
Discover More
Discover More
Discover More
Press Release
event
RTNova
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
June 10, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
June 3, 2024
Discover More
Discover More
Discover More
Press Release
Calidi Biotherapeutics to Present at Jefferies Healthcare Conference
June 2, 2022
Discover More
Press Release
Calidi Biotherapeutics Granted US Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy
May 24, 2022
Discover More
Press Release
Calidi Biotherapeutics Announces Appointment of Alfonso "Chito" Zulueta, Former President of International for Eli Lilly, to Its Board of Directors
February 4, 2022
Discover More
Press Release
Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
February 2, 2022
Discover More
Press Release
Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference
November 5, 2021
Discover More
Press Release
Calidi Biotherapeutics Announces Presentation at 6th Annual Oncolytic Virotherapy Summit
October 25, 2021
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Annual Meeting – SITC 2023 – Nov 1st to 5th 2023 in San Diego, CA, USA.
November 3, 2023
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy
December 13, 2022
Discover More
Discover More
Publication
event
NeuroNova (NNV)
NeuroNova (NNV)
NeuroNova
Supernova
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
August 22, 2021
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies
August 15, 2020
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects
August 15, 2020
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.
May 25, 2020
Discover More
Discover More
Media
Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - Bernard Fox, PhD,
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.
February 3, 2024
Discover More
Media
Big Biz TV - Allan Camaisa
December 4, 2023
Discover More
Media
Big Biz TV - Stephen Thesing
December 4, 2023
Discover More
In The News
Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
October 9, 2023
Discover More
Discover More
In The News
Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
October 9, 2023
Discover More
Discover More